Kyverna Therapeutics, Inc. (KYTX)
(Delayed Data from NSDQ)
$7.25 USD
-0.60 (-7.64%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $7.24 -0.01 (-0.14%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
KYTX 7.25 -0.60(-7.64%)
Will KYTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for KYTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KYTX
Biotech Stock Roundup: LXRX Up on Regulatory Update, SAVA, LXEO Down on Updates
Kyverna (KYTX) Gets RMAT Designation for CAR T-Cell Product
KYTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for KYTX
JMP Securities healthcare analysts hold an analyst/industry conference call
JMP Securities healthcare analysts hold an analyst/industry conference call
Cell Therapy Mostly Used For Blood Cancer Shows Efficacy In Autoimmune Diseases As Well, But There Are Challenges
3 Best Stocks to Buy Now, 7/18/2024, According to Top Analysts
Buy Rating on Kyverna Therapeutics: KYV-101’s Promising Clinical Advances and Market Potential